UK markets closed

Viracta Therapeutics, Inc. (RYI.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.7700+0.0150 (+1.99%)
At close: 08:20AM CEST
Show:
Balance sheet
Cash flow
Annual

Income statement

Currency in USD. All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
0
0
0
0
0
Operating expenses
Research development
26,862
33,369
26,262
23,861
13,467
Selling general and administrative
23,471
17,324
24,327
15,437
5,348
Total operating expenses
50,333
50,693
50,589
25,798
18,815
Operating income or loss
-50,333
-50,693
-50,589
-25,798
-18,815
Interest expense
529
3,704
577
491
216
Total other income/expenses net
-6
-6
798
-88,511
-34
Income before tax
-50,318
-51,058
-49,197
-114,762
-19,017
Income from continuing operations
-50,318
-51,058
-49,197
-114,762
-19,017
Net income
-50,318
-51,058
-49,197
-114,762
-19,017
Net income available to common shareholders
-50,318
-51,058
-49,197
-114,762
-19,017
Basic EPS
-1.24
-
-1.30
-3.60
-0.51
Diluted EPS
-1.24
-
-1.30
-3.60
-0.51
Basic average shares
38,507
-
37,791
31,870
36,995
Diluted average shares
38,507
-
37,791
31,870
36,995